Jose Vila
Instituto Politécnico Nacional
18 Papers
55 Citations
Jose Vila is an academic researcher from Instituto Politécnico Nacional. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 11, co-authored 16 publications. Previous affiliations of Jose Vila include European Institute of Oncology & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy
Shannon K. Swisher,Jose Vila,Susan L. Tucker,Isabelle Bedrosian,Simona F. Shaitelman,Jennifer K. Litton,Benjamin Smith,Abigail S. Caudle,Henry Mark Kuerer,Elizabeth A. Mittendorf +9 more
TL;DR: Patients undergoing BCT after neoadjuvant chemotherapy have excellent rates of 5-year LRR-free survival that are affected by molecular subtype and by response to neoadJuvant chemotherapy.
130
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment
Elizabeth A. Mittendorf,Jose Vila,Susan L. Tucker,Mariana Chavez-MacGregor,Benjamin Smith,W. Fraser Symmans,Aysegul A. Sahin,Gabriel N. Hortobagyi,Kelly K. Hunt +8 more
TL;DR: The Neo-Bioscore improves the previously validated CPS+EG staging system and allows its application in ERBB2-positive patients and is recommended that treatment response and biologic markers be incorporated into the American Joint Committee on Cancer staging system.
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer
Jose Vila,Jose Vila,Elizabeth A. Mittendorf,G. Farante,Roland L. Bassett,Paolo Veronesi,Viviana Galimberti,N. Peradze,Michael C. Stauder,Mariana Chavez-MacGregor,Jennifer F. Litton,Lei Huo,Henry Mark Kuerer,Kelly K. Hunt,Abigail S. Caudle +14 more
TL;DR: A nomogram to predict axillary response to NAC in patients with cN1 disease that can assist clinicians in treatment planning is developed and may help to inform treatment decisions.
77
Second Axillary Sentinel Lymph Node Biopsy for Breast Tumor Recurrence: Experience of the European Institute of Oncology.
Mattia Intra,Giuseppe Viale,Giuseppe Viale,Jose Vila,Chiara Maria Grana,Antonio Toesca,Oreste Gentilini,Viviana Galimberti,Paolo Veronesi,Paolo Veronesi,Alberto Luini,Nicole Rotmensz,Vincenzo Bagnardi,Vincenzo Bagnardi,Denise Mattar,Marco Colleoni +15 more
TL;DR: A second SLNB should be considered for patients with operable local breast tumor recurrence who underwent conservative surgery and had negative SLNB results, because the procedure is technically feasible and accurate for selected patients.
Ipsilateral axillary recurrence after breast conservative surgery: The protective effect of whole breast radiotherapy.
Oreste Gentilini,Edoardo Botteri,Maria Cristina Leonardi,Nicole Rotmensz,Jose Vila,Nickolas Peradze,Maria Virginia Thomazini,B. Jereczek,Viviana Galimberti,Alberto Luini,Paolo Veronesi,Roberto Orecchia +11 more
TL;DR: In this large series of women with T1 breast cancer and negative sentinel lymph node treated by BCS, WBRT lowered the risk of axillary recurrence by two thirds as compared to PBI.
41